On July 16, Atai Beckley surged 32.93% in regular trading, trading at $7.125/share, with turnover of $910 million. The sharp rally was driven by the announcement that pharmaceutical giant Eli Lilly will acquire the clinical-stage biotech company for up to $3.8 billion at a premium.

According to multiple reports, Eli Lilly confirmed the acquisition of Atai Beckley to strengthen its presence in mental health therapeutics, particularly targeting treatment-resistant depression and other complex psychiatric disorders. Prior to the deal announcement, Atai Beckley had a market capitalization of approximately $1.97 billion, implying a significant premium in the transaction. The deal aims to integrate Atai Beckley's research pipeline and technical expertise in psychedelic-based therapies to accelerate the development of novel treatments.

Atai Beckley is a clinical-stage biopharmaceutical company focused on developing therapeutics for depression, anxiety, addiction, and other mental health disorders. Its pipeline includes BPL-003, an intranasal formulation in Phase 2 clinical studies for treatment-resistant depression, among other candidates.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)